The medication is commonly used to help with symptoms related to physical discomfort and systemic imbalance arising from venous conditions. It is relevant when supportive symptom management is appropriate across its therapeutic domains, and is commonly used to address symptoms of chronic venous insufficiency and hemorrhoidal disease.

This formulation is applied in conditions characterized by periods of heightened symptoms in the lower limbs, and is applied in addressing symptom clusters that may become intense or disruptive, such as the persistent feeling of heavy legs, localized pain, and nocturnal cramps. The treatment may assist with managing associated swelling (edema), which may contribute to improved comfort.

Ardium 500 is also used across conditions presenting with acute or episodic manifestations related to hemorrhoidal disease, generally supporting symptomatic relief for the intense anal pain and localized swelling often associated with an acute attack. This supportive approach assists with easing the overall symptom burden.

---

Quick Fact: Supports Management of Heavy Legs and Edema

Regulatory References

1. Health Canada Product Information

The official eligibility profile for Ardium 500 (Micronized Purified Flavonoid Fraction) defines the populations who can and cannot use the medicine based on regulatory labeling. The following classifications are derived strictly from government-approved documents.

Absolute Exclusion and Contraindications

The medicine is strictly contraindicated for any individual with known hypersensitivity or allergy to the active substance or to any of the product’s excipients. This is the single absolute prohibition listed in the regulatory documents.

Age-Related and Physiological Restrictions

Ardium 500 is intended for the adult population. Its safety and efficacy have not been established in children and adolescents under 18 years of age, and therefore use is not recommended for this age group.

Regarding physiological life stages, use during pregnancy is preferable to avoid as a precautionary measure due to limited human data. Use is not recommended for women who are breastfeeding because a risk to the newborns or infants cannot be excluded.

Condition-Specific Eligibility

No explicit contraindication or non-eligibility rule is documented in the official labeling based on the patient's status regarding renal (kidney) or hepatic (liver) impairment. Furthermore, when used for an acute hemorrhoidal attack, the treatment is restricted to short-term symptomatic administration.

Interactions with other medicines and products

Official Regulatory Information for Ardium 500

The official drug interaction profile for Ardium 500, which contains the active ingredient Micronized Purified Flavonoid Fraction (MPFF), is defined exclusively by the information recorded in governmental regulatory documents, such as the Summary of Product Characteristics (SmPC) and equivalent prescribing information.

Interaction Scope Summary

Interaction Category	Official Regulatory Status
Documented Drug-Drug Interactions	None documented as clinically relevant.
Metabolic or Transporter-Based Interactions	Not applicable. Official regulatory documents confirm that no formal interaction studies have been performed.
Timing Rules / Administration Separation	None documented. No mandatory timing or separation requirements are specified in the official labeling.
Interactions with Food, Alcohol, or Supplements	None documented. Official labels note that interactions with food and drink are not applicable.

Interaction Classifications (High-Level)

The regulatory review classifies the product based on post-marketing surveillance rather than formal interaction studies.

• Clinically Relevant Interaction Severity: Not classified as clinically significant.
• Official Restrictions: No combinations are formally restricted or listed as contraindicated due to an interaction risk based on official regulatory data.

Resulting Interaction Structure

The official interaction statements explicitly confirm that no studies on potential drug-drug interactions have been conducted with the active ingredient. Consistent with this finding, regulatory authorities report that no clinically relevant interactions have been noted or reported in post-marketing experience since the product’s approval. This finding confirms the absence of known, clinically significant pharmacokinetic or pharmacodynamic interactions in the official labeling.

Ardium 500, containing a Micronized Purified Flavonoid Fraction (MPFF) primarily of diosmin and hesperidin, exerts its action selectively on the vascular system. Its principal biological targets are the venous walls and the microcirculation (capillaries and venules).

At the macrocirculatory level, the active substances are proposed to act as venotonics, interacting with the adrenergic system to prolong the activity of parietal noradrenaline. This neuromodulation leads to increased venous tone and reduced venous capacitance and venous distensibility. The resulting systemic-level physiological consequence is a decrease in venous emptying time.

In the microcirculation, MPFF functions as a vasculoprotector. It inhibits the release of inflammatory mediators, such as certain prostaglandins and free radicals, by decreasing leukocyte activation and their adhesion to the endothelial lining. This anti-inflammatory interaction leads to the reinforcement of capillary resistance and the normalization of capillary permeability.

Official Administration Guidelines for Ardium 500

The administration of Ardium 500 is strictly standardized, defining the required dose and timing based on the specific condition being addressed. As an oral medication, it is supplied only as a 500 mg film-coated tablet containing the Micronized Purified Flavonoid Fraction (MPFF).

The tablets must be taken via the oral route and are officially prescribed for administration at meal times to ensure proper context for use.

Labeled Dosing Regimens

Clinical Context	Total Daily Dose	Administration Schedule
Chronic Venous Insufficiency	1000 mg (two 500 mg tablets)	Administered in two divided doses (typically midday and evening).
Acute Hemorrhoidal Attack (Initial Phase)	3000 mg (six 500 mg tablets)	Administered daily for the first 4 days.
Acute Hemorrhoidal Attack (Tapering Phase)	2000 mg (four 500 mg tablets)	Administered daily for the subsequent 3 days.

Population and Procedural Constraints

The usage protocol is defined by specific procedural constraints and age-group rules. The safety and efficacy of Ardium 500 have not been established for use in individuals under 18 years of age. For all users, if a dose is missed, instructions advise against taking a double dose to compensate. Furthermore, the high-dose regimen for acute hemorrhoidal attacks is a mandatory short-term, 7-day course, and the administration protocol does not preclude the need for specialized medical examination if symptoms persist beyond 15 days.

Ardium 500: Recent Clinical Evidence

Ardium 500 is a venoactive drug formulated as a micronized purified flavonoid fraction (MPFF), containing 450 mg of diosmin (90%) and 50 mg of hesperidin (10%). The micronized form is specifically designed to enhance absorption and bioavailability, which is a key factor in its clinical efficacy.

---

Chronic Venous Insufficiency (CVI)

Extensive clinical research, including large-scale trials, consistently supports the use of this MPFF combination in the management of Chronic Venous Insufficiency. Studies demonstrate that it significantly alleviates the cardinal symptoms of CVI, such as leg heaviness, aching, and nocturnal cramping, across various stages of the disease (CEAP classes 0-4).

The drug works by improving venous tone, reducing capillary hyperpermeability, and enhancing lymphatic drainage. Objective measurements, utilizing techniques like plethysmography, have shown improvements in venous outflow parameters compared to placebo. A key finding is its ability to reduce edema (swelling) in the lower limbs, which contributes to an improved patient quality of life. For patients with advanced CVI and venous leg ulcers, MPFF, when used as an adjunct to standard therapy (like compression dressings), has been shown to accelerate the rate of ulcer healing.

Clinical Area	Key Efficacy Findings	Impact on Patient
Chronic Venous Symptoms	Significant reduction in leg pain, heaviness, and cramping.	Improved daily comfort and mobility.
Edema	Measurable decrease in lower limb swelling (leg circumference).	Reduction in tissue congestion.
Venous Leg Ulcers	Accelerated complete healing rate when combined with compression.	Faster recovery from advanced disease.

---

Hemorrhoidal Disease

Clinical evidence also indicates that the MPFF combination is effective in treating symptoms of hemorrhoidal disease. It has been shown to reduce symptoms of acute hemorrhoidal attacks, and may also be beneficial in the long-term management to prevent recurrence.

Common questions about Ardium 500 (FAQ)

---

Q: What is the primary purpose or class of Ardium 500?

According to official product information, this medicine is classified as a phlebotropic and vasculoprotective agent. This means it is formulated to provide support to the body's venous circulation and the integrity of the capillaries (tiny blood vessels).

---

Q: Can men and women use Ardium 500?

Regulatory documents indicate the medicine is intended for the adult population. However, official safety constraints include specific non-recommendations for use in women who are pregnant or are breastfeeding due to limited data.

---

Q: What is the mechanism of action for Ardium 500?

Official information describes a dual mechanism. It acts as a venotonic, which contributes to increasing the tone of the vein walls. It also functions as a vasculoprotector, which may reinforce the resistance of capillaries and help normalize their permeability.

---

Q: Can Ardium 500 be used by children or teenagers under 18?

Official labeling states that the safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. For this reason, use is generally not recommended for this age group.

---

Q: Does Ardium 500 interfere with blood thinners like Warfarin?

Official regulatory documents confirm that no formal interaction studies have been conducted for this product. However, regulatory information reports that no clinically relevant interactions have been noted during post-marketing experience. Individuals taking any blood thinners, such as Warfarin, may wish to discuss the use of this product with a healthcare professional.

---

Q: Does Ardium 500 interact with grapefruit or grapefruit juice?

Official regulatory labeling and product information state that no interactions with food, alcohol, or supplements are documented. Interactions with food and drink are generally considered not applicable based on official regulatory data.

---

Q: What are the differences between the 500 mg and 1000 mg tablets?

Official administration guidelines state that the medication is supplied only as a single strength, the 500 mg film-coated tablet. Higher doses mentioned in dosing schedules are achieved by taking more than one 500 mg tablet.

---

Q: Can I drink alcohol while taking Ardium 500?

According to official regulatory labeling, no interactions with food, alcohol, or supplements have been documented. Interactions with food and drink are generally noted as not applicable in the official product information.

How to Store and Dispose of Ardium 500

The storage and disposal of Ardium 500 (Micronized Purified Flavonoid Fraction) must strictly adhere to the conditions specified in official regulatory labeling to ensure product stability and safety.

Official Storage and Handling

Requirement	Constraint
Temperature	Store below 30°C.
Packaging	Keep the medicine in the original carton.
Child Safety	Must be kept out of the sight and reach of children.
Shelf-Life	Do not use after the expiry date printed on the box.

The regulatory profile defines that the product must remain within these constraints until the last day of the expiration month.

Disposal Instructions

Unused or expired tablets must not be disposed of in the sewer system or with household trash. The official protocol requires taking the unwanted medicine to a pharmacist for appropriate disposal, which helps to ensure the protection of the environment.